Abstract:Objective To assess the therapeutic effects of flupentixol and melitracen tablets combined with Saccharomyces boulardii on patients with diarrhea-predominant irritable bowel syndrome (IBS) accompanied with anxiety and depression.Methods This multi-center,randomized,prospective study enrolled 84 patients with diarrhea-predominant IBS who were divided into combined treatment group (42 patients) and control group (42 patients).Saccharomyces boulardii was administrated in both of the groups,and flupentixol and melitracen was added in combined treatment group.The treatment course was four weeks.The gastrointestinal symptoms and mood disorders were evaluated before treatment,one week and four weeks after treatment.Adverse reactions were also observed.Chi-square test was performed for statistical analysis.Results At the end of one week after treatment,the efficacy rates of gastrointestinal symptoms improvement of combined treatment group and control group were 31.0％ (13/42) and 23.8％ (10/42),and there was no statistically significant difference (P＞0.05).At the end of four weeks after treatment,the efficacy rate of gastrointestinal symptoms improvement of combined treatment group was 92.5％ (37/40),which was higher than that of control group (73.2％,30/41),and the difference was statistically significant (x2 =5.291,P =0.037).At the end of one week after treatment,the efficacy rates of Hamilton Depression Scale score improvement of combined treatment group and control group were 31.6％ (12/38) and 12.1％ (4/33),and there was no statistically significant difference (P＞0.05).At the end of four weeks after treatment,the efficacy rates of Hamilton Depression Scale score improvement of combined treatment group was 63.9％ (23/36),which was higher than that of control group (34.4％,11/42),and the difference was statistically significant (x2 =6.433,P=0.043).At the end of one week and four weeks after treatment,the efficacy rates of Hamilton Depression Scale score improvement of combined treatment group were 35.7％ (15/42) and 80.0％ (32/40),which were higher than those of control group (15.4％,6/39 and 34.2％,13/38),and the differences were statistically significant (x2 =9.759,P=0.007; x2 =17.105,P＜0.01).One week after treatment,the adverse events rates of combined treatment group and control group were 4.8％ (2/42) and 4.8％ (2/42) ; four weeks after treatment,the adverse events rates of combined treatment group and control group were 2.5％ (1/40) and 2.4％ (1/41).There was no statistically significant difference in adverse events rates between two groups (both P＞0.05).Conclusions Flupentixol and melitracen combined with Saccharomyces boulardii treatment could not only improve the anxiety and depression symptoms of patients with diarrhea-predominant IBS,but also effectively improve gastrointestinal symptoms.The efficacy of combined treatment is better than monotherapy Saccharomyces boulardii alone treatment.

A Clinical Trial of Alprazolam and Fluoxetine for the Treatment of Severe Refractory Irritable Bowel Syndrome

Randomized,multicenter,double blind comparative trial of reboxetine in the treatment of depression with or without anxiety

A controlled trial of olanzapine and fluoxetine in treatment of negative symptoms of schizophrenia

A comparison study of sertraline,venlafxin and alprazolam in treatment of generalized anxiety disorder

A clinical trial of alprazolam and fluoxetine for the treatment of the intractable functional gastrointestinal disorders

Treatment of Irritable Bowel Syndrome with Drotaverine Hydrochloride: A Multicentre Clinical Trial

A clinical trial of fFluoxetine and Paroxetine for the treatment of the irritable bowel syndrome

Fluoxetine Ameliorates Symptoms of Refractory Chronic Prostatitis/chronic Pelvic Pain Syndrome.

Efficacy of fluoxetine combined with psychological intervention for treatment of depressive patients with insomnia

Evaluation of therapeutic effects of flupentixol and melitracen combined with Saccharomyces boulardii on patients with diarrhea-predominant irritable bowel syndrome accompanied with anxiety and depression

Alprazolam Use Improves Psychological Status and Reduces Hospitalization Costs in Patients with Paroxysmal Supraventricular Tachycardia Underwent Radiofrequency Catheter Ablation

SF-36 quality of life in effectiveness ssessment for irritable bowel syndrome

Short-Term Effects of Flupentixol-Melitracen on Regional Brain Function in Patients with Irritable Bowel Syndrome: an Fmri Study

Unveiling the efficacy of paroxetine and gabapentin in ulcerative colitis patients in remission with co-existing IBS-like symptoms: a single-blinded randomized clinical trial

Efficacy of acupuncture in refractory irritable bowel syndrome patients: a randomized controlled trial

A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression

Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial

Comparative studty of the drug treatment in depressive patients with anxious or insomnia symptoms

Clinical effect of reboxetine in the treatment of anxiety in depressive patients

Comparison of Reboxetine with Fluoxetine in Treatment of Depression: a Randomized, Double-Blind, Multicenter Study

Multipronged Electronic Health Record Analysis of Antidepressant Effectiveness on Depression Remission in Patients With Concurrent Depression and Irritable Bowel Syndrome